Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation
<p>Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2)...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , |
| Published: |
2019
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513554529386496 |
|---|---|
| author | Kodappully S. Siveen (4246150) |
| author2 | Kirti S. Prabhu (4246144) Aeijaz S. Parray (14152734) Maysaloun Merhi (4246147) Abdelilah Arredouani (10914455) Mohamed Chikri (2243) Shahab Uddin (154400) Said Dermime (79420) Ramzi M. Mohammad (14152737) Martin Steinhoff (5340194) Ibrahim A. Janahi (14070765) Fouad Azizi (14152740) |
| author2_role | author author author author author author author author author author author |
| author_facet | Kodappully S. Siveen (4246150) Kirti S. Prabhu (4246144) Aeijaz S. Parray (14152734) Maysaloun Merhi (4246147) Abdelilah Arredouani (10914455) Mohamed Chikri (2243) Shahab Uddin (154400) Said Dermime (79420) Ramzi M. Mohammad (14152737) Martin Steinhoff (5340194) Ibrahim A. Janahi (14070765) Fouad Azizi (14152740) |
| author_role | author |
| dc.creator.none.fl_str_mv | Kodappully S. Siveen (4246150) Kirti S. Prabhu (4246144) Aeijaz S. Parray (14152734) Maysaloun Merhi (4246147) Abdelilah Arredouani (10914455) Mohamed Chikri (2243) Shahab Uddin (154400) Said Dermime (79420) Ramzi M. Mohammad (14152737) Martin Steinhoff (5340194) Ibrahim A. Janahi (14070765) Fouad Azizi (14152740) |
| dc.date.none.fl_str_mv | 2019-02-07T18:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1038/s41598-018-37469-8 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Evaluation_of_cationic_channel_TRPV2_as_a_novel_biomarker_and_therapeutic_target_in_Leukemia-Implications_concerning_the_resolution_of_pulmonary_inflammation/21598107 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Leukemia Leukemic Blast Cells (LBCs) Oncogenic Activity Molecular Expression Pulmonary Dysfunction Airway Inflammation |
| dc.title.none.fl_str_mv | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Additionally, functional full length isoform and nonfunctional short form pore-less variant of TRPV2 protein were up-regulated and down-regulated respectively in LBCs. However, the opposite was found in PBMCs. TRPV2 silencing or pharmacological targeting by Tranilast (TL) or SKF96365 (SKF) triggered caspace-mediated apoptosis and cell cycle arrest. TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca2+ activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation. Challenging lung airway epithelial cells (AECs) with LBCs decreased (by more than 50%) transepithelial resistance (TER) denoting barrier function alteration. Importantly, TL prevented such loss in TER. Therefore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pulmonary inflammation) who might be suitable for a novel [adjuvant] therapeutic strategy based on TL.</p><h2>Other Information</h2> <p> Published in: Scientific Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1038/s41598-018-37469-8" target="_blank">http://dx.doi.org/10.1038/s41598-018-37469-8</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a62cfb6cf07f9b044e32ca782c9dab9e |
| identifier_str_mv | 10.1038/s41598-018-37469-8 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21598107 |
| publishDate | 2019 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammationKodappully S. Siveen (4246150)Kirti S. Prabhu (4246144)Aeijaz S. Parray (14152734)Maysaloun Merhi (4246147)Abdelilah Arredouani (10914455)Mohamed Chikri (2243)Shahab Uddin (154400)Said Dermime (79420)Ramzi M. Mohammad (14152737)Martin Steinhoff (5340194)Ibrahim A. Janahi (14070765)Fouad Azizi (14152740)Biomedical and clinical sciencesClinical sciencesOncology and carcinogenesisLeukemiaLeukemic Blast Cells (LBCs)Oncogenic ActivityMolecular ExpressionPulmonary DysfunctionAirway Inflammation<p>Patients treated during leukemia face the risk of complications including pulmonary dysfunction that may result from infiltration of leukemic blast cells (LBCs) into lung parenchyma and interstitium. In LBCs, we demonstrated that transient receptor potential vanilloid type 2 channel (TRPV2), reputed for its role in inflammatory processes, exhibited oncogenic activity associated with alteration of its molecular expression profile. TRPV2 was overexpressed in LBCs compared to normal human peripheral blood mononuclear cells (PBMCs). Additionally, functional full length isoform and nonfunctional short form pore-less variant of TRPV2 protein were up-regulated and down-regulated respectively in LBCs. However, the opposite was found in PBMCs. TRPV2 silencing or pharmacological targeting by Tranilast (TL) or SKF96365 (SKF) triggered caspace-mediated apoptosis and cell cycle arrest. TL and SKF inhibited chemotactic peptide fMLP-induced response linked to TRPV2 Ca2+ activity, and down-regulated expression of surface marker CD38 involved in leukemia and lung airway inflammation. Challenging lung airway epithelial cells (AECs) with LBCs decreased (by more than 50%) transepithelial resistance (TER) denoting barrier function alteration. Importantly, TL prevented such loss in TER. Therefore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pulmonary inflammation) who might be suitable for a novel [adjuvant] therapeutic strategy based on TL.</p><h2>Other Information</h2> <p> Published in: Scientific Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1038/s41598-018-37469-8" target="_blank">http://dx.doi.org/10.1038/s41598-018-37469-8</a></p>2019-02-07T18:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1038/s41598-018-37469-8https://figshare.com/articles/journal_contribution/Evaluation_of_cationic_channel_TRPV2_as_a_novel_biomarker_and_therapeutic_target_in_Leukemia-Implications_concerning_the_resolution_of_pulmonary_inflammation/21598107CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215981072019-02-07T18:00:00Z |
| spellingShingle | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation Kodappully S. Siveen (4246150) Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Leukemia Leukemic Blast Cells (LBCs) Oncogenic Activity Molecular Expression Pulmonary Dysfunction Airway Inflammation |
| status_str | publishedVersion |
| title | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation |
| title_full | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation |
| title_fullStr | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation |
| title_full_unstemmed | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation |
| title_short | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation |
| title_sort | Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation |
| topic | Biomedical and clinical sciences Clinical sciences Oncology and carcinogenesis Leukemia Leukemic Blast Cells (LBCs) Oncogenic Activity Molecular Expression Pulmonary Dysfunction Airway Inflammation |